首页> 美国卫生研究院文献>Cell Death Disease >Novel β-phenylacrylic acid derivatives exert anti-cancer activity by inducing Src-mediated apoptosis in wild-type KRAS colon cancer
【2h】

Novel β-phenylacrylic acid derivatives exert anti-cancer activity by inducing Src-mediated apoptosis in wild-type KRAS colon cancer

机译:新型β-苯基丙烯酸衍生物通过诱导Src介导的野生型KRAS结肠癌细胞凋亡发挥抗癌活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Many stress conditions including chemotherapy treatment is known to activate Src and under certain condition Src can induce the apoptotic signal via c-Jun N-terminal kinase (JNK) activation. Here we report that the newly synthesized β-phenylacrylic acid derivatives, MHY791 and MHY1036 (MHYs), bind to epidermal growth factor receptor (EGFR) tyrosine kinase domains and function as EGFR inhibitors, having anti-cancer activities selectively in wild-type KRAS colon cancer. Mechanistically, MHYs-induced Src/JNK activation which enhanced their pro-apoptotic effects and therefore inhibition of Src by the chemical inhibitor PP2 or Src siRNA abolished the response. In addition, MHYs generated reactive oxygen species and increased ER stress, and pretreatment with antioxidant-inhibited MHY-induced ER stress, Src activation, and apoptosis. Furthermore, the irreversible EGFR inhibitor PD168393 also activated Src while the reversible EGFR inhibitor gefitinib showed the opposite effect, indicating that MHYs are the irreversible EGFR inhibitor. Collectively, Src can play a key role in apoptosis induced by the novel EGFR inhibitor MHYs, suggesting that activation of Src might prove effective in treating EGFR/wild-type KRAS colon cancer.
机译:已知包括化学疗法在内的许多应激条件都可以激活Src,在某些条件下Src可以通过c-Jun N端激酶(JNK)激活诱导凋亡信号。在这里,我们报告新合成的β-苯基丙烯酸衍生物MHY791和MHY1036(MHYs)与表皮生长因子受体(EGFR)酪氨酸激酶域结合并起EGFR抑制剂的作用,在野生型KRAS结肠中选择性地具有抗癌活性癌症。从机制上讲,MHYs诱导的Src / JNK激活增强了其促凋亡作用,因此被化学抑制剂PP2或Src siRNA抑制了Src,从而消除了应答。此外,MHYs会产生活性氧并增加ER应激,并用抗氧化剂抑制MHY诱导的ER应激,Src活化和凋亡进行预处理。此外,不可逆EGFR抑制剂PD168393也激活了Src,而可逆EGFR抑制剂吉非替尼则显示相反的作用,表明MHYs是不可逆EGFR抑制剂。集体,Src可以在新型EGFR抑制剂MHYs诱导的细胞凋亡中起关键作用,这表明Src的激活可能被证明可以有效治疗EGFR /野生型KRAS结肠癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号